All In Biotech

Drug Trial Radar · NCT04866017

A Study to Compare Ociperlimab Plus Tislelizumab Versus Durvalumab Following Concurrent Chemoradiotherapy (cCRT) in Participants With Stage III Unresectable Non-Small Cell Lung Cancer

A Phase 3, Randomized, Open-Label Study to Compare Ociperlimab (BGB-A1217) Plus Tislelizumab (BGB-A317) Versus Durvalumab in Patients With Locally Advanced, Unresectable, PD-L1-Selected Non-Small Cell Lung Cancer Whose Disease Has Not Progressed After Concurrent Chemoradiotherapy

Last checked: Nov 19, 2026Latest source record: Oct 31, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

63

Actual

Start

Jun 17, 2021

Primary completion

Oct 17, 2023

Study completion Oct 17, 2023

Sponsor

Lead sponsor
BeiGeneBeOne Medicines (BeiGene) (ONC)
Sponsor type
Industry
First posted
Apr 29, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study was to evaluate the safety and efficacy of ociperlimab in combination with tislelizumab compared to durvalumab in adults with stage III unresectable PD-L1-selected non-small cell lung cancer whose disease has not progressed after cCRT.

Conditions

  • Non Small Cell Lung Cancer

Interventions

  • TislelizumabDrug

    200 mg intravenously every three weeks

  • DurvalumabDrug

    10 milligrams per kilogram (mg/kg) intravenously once every 2 weeks (or 1500 mg intravenously once every 4 weeks where the dosage has been approved by a local health authority)

  • OciperlimabDrug

    900 milligrams (mg) intravenously every three weeks

  • ChemotherapyDrug

    The chemotherapy regimen for the study treatment was selected at the investigator's discretion and may include one of the following options: * Cisplatin (50 mg/m²) on days 1 to 5 of each cycle, combined with etoposide (50 mg/m²) on days 1 and 8, both administered intravenously for 2 cycles. Each cycle was 28 days. * Carboplatin (AUC 2) weekly for 6 weeks, combined with paclitaxel (40-50 mg/m²) weekly for 6 weeks, both administered intravenously. * Cisplatin (75 mg/m²) combined with pemetrexed (500 mg/m²) on day 1 of each cycle, administered intravenously for 2 cycles. Each cycle was 21 days. * Carboplatin (AUC 5) combined with pemetrexed (500 mg/m²) on day 1 of each cycle, administered intravenously for 2 cycles. Each cycle was 21 days. The pemetrexed plus platinum regimen was only for participants with non-squamous histology.

  • RadiotherapyRadiation

    All participants recieved radiotherapy using either a standardized 3-dimensional conformal radiotherapy technique, or intensity modulated radiotherapy (IMRT) on a linear accelerator delivering a beam energy of ≥ 6 MV. The total dose of radiotherapy was 60 Gy, administered in 30 once-daily fractions of 2 Gy and 5 fractions per week for 6 weeks.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-Free Survival (PFS) as Assessed by the Independent Review Committee (IRC)Time frame: From randomization through to the end of study, planned duration was 20 months

Locations

35 sites in 5 countries. Site status is shown where the registry gives one.

  • XCancer/Centeral Care Center

    Bolivar, Missouri

  • Gold Coast University Hospital

    Gold Coast, Australia

  • Hollywood Private Hospital

    Perth, Australia

  • Southern Medical Day Care Centre

    Wollongong, New South Wales, Australia

  • Townsville Hospital

    Douglas, Queensland, Australia

  • Lyell McEwin Hospital

    Elizabeth Vale, South Australia, Australia

  • Royal Hobart Hospital

    Hobart, Tasmania, Australia

  • Cabrini Hospital

    Malvern, Victoria, Australia

  • Peking University Third Hospital

    Beijing, China

  • Changzhou Cancer Hospital

    Changzhou, China

  • Jieyang People'S Hospital (Jieyang Affiliated Hospital, Sun Yat-Sen University )

    Jieyang, China

  • Beijing Cancer Hospital

    Beijing, Beijing Municipality, China

  • Chongqing University Cancer Hospital

    Chongqing, Chongqing Municipality, China

  • Fujian Cancer Hospital

    Fuzhou, Fujian, China

  • Nanfang Hospital of Southern Medical University

    Guangzhou, Guangdong, China

  • The First Affiliated Hospital, Sun Yat-sen University

    Guangzhou, Guangdong, China

  • Hunan Cancer Hospital - GCP Office

    Changsha, Hunan, China

  • Nanjing First Hospital

    Nanjing, Jiangsu, China

  • The First Affiliated Hospital of Soochow University Branch Shizi

    Suzhou, Jiangsu, China

  • The First Affiliated Hospital of Nanchang University Branch Donghu

    Nanchang, Jiangxi, China

  • Jilin Cancer Hospital

    Changchun, Jilin, China

  • The First Hospital of Jilin University

    Changchun, Jilin, China

  • General Hospital of Ningxia Medical University

    Yinchuan, Ningxia, China

  • Shandong Cancer Hospital and Institute, Shandong First Medical University

    Jinan, Shandong, China

  • Fudan University Shanghai Cancer Center

    Shanghai, Shanghai Municipality, China

  • West China Hospital, Sichuan University

    Chengdu, Sichuan, China

  • Tianjin Medical University Cancer Institute & Hospital

    Tianjin, Tianjin Municipality, China

  • Sir Run Run Shaw Hospital, Zhejiang University, School of Medicine

    Hangzhou, Zhejiang, China

  • Instituto Oncologico Dr. Rosell

    Barcelona, Spain

  • Ico Girona

    Girona, Spain

  • Hospital Universitario Fundación Jiménez Díaz

    Alcorcón, Madrid, Spain

  • Changhua Christian Hospital

    Changhua, Taiwan

  • Chung Shan Medical University Hospital

    Taichung, Taiwan

  • Taichung Veterans General Hospital

    Taichung, Taiwan

  • Taipei Veterans General Hospital

    Taipei, Taiwan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.